Alpha Tau Medical Ltd. - (DRTS) closed at $13.36 on November 12, 2026, down 4.7% from the previous close, on volume of 572,886 shares (30-day average 474,622).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Diagonal Call Spread | 20-Nov-26 : 19-Feb-2712.5 : 15 C | 400 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Alpha Tau Announces Review of REGAIN Glioblastoma Data
TipRanks (Thu, 12-Nov 9:36 AM ET)
Globe Newswire (Thu, 12-Nov 8:30 AM ET)
Alpha Tau upgraded at Piper Sandler on catalyst path
Seeking Alpha News (Wed, 11-Nov 11:32 AM ET)
Globe Newswire (Thu, 29-Oct 12:14 PM ET)
Globe Newswire (Thu, 22-Oct 8:30 AM ET)
Market Chameleon (Mon, 19-Oct 5:11 AM ET)
Globe Newswire (Mon, 19-Oct 8:30 AM ET)
Alpha Tau to Participate in October Investor Conferences
Globe Newswire (Mon, 5-Oct 9:45 AM ET)
Alpha Tau to Participate in September Investor Conferences
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Globe Newswire (Mon, 31-Aug 8:00 AM ET)
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Alpha Tau Medical Ltd. - trades on the NASDAQ stock market under the symbol DRTS.
As of November 13, 2026, DRTS stock price declined to $13.18 with 141,306 million shares trading.
DRTS has a beta of 1.64, meaning it tends to be more sensitive to market movements. DRTS has a correlation of 0.09 to the broad based SPY ETF.
DRTS has a market cap of $1.22 billion. This is considered a Small Cap stock.
Last quarter Alpha Tau Medical Ltd. - reported $0 in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-230,136 and missed earnings estimates by -$.36.
In the last 3 years, DRTS traded as high as $15.79 and as low as $1.75.
The top ETF exchange traded funds that DRTS belongs to (by Net Assets): IEFA, SCZ, IZRL, EIS, IXUS.
DRTS has outperformed the market in the last year with a price return of +232.0% while the SPY ETF gained +10.9%. However, in the short term, DRTS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.0% vs -2.6% return in SPY. But in the last 2 weeks, DRTS shares have fared better than the market returning -0.4% compared to SPY -2.5%.
DRTS support price is $12.89 and resistance is $13.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRTS shares will trade within this expected range on the day.
